Published: May 05, 2021
Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end
RUBY trial of EDIT-301 for sickle cell disease active and recruiting
Preclinical ocular data presented at ARVO supports in vivo gene editing
$723 million
as of March 31, 2021
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021.
“Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for our two clinical-stage medicines,” said James C. Mullen, Chairman, President and Chief Executive Officer, Editas Medicine. “We are pleased to announce Dr. Mark Shearman will be joining Editas as Chief Scientific Officer in June 2021. Mark has an outstanding track record of drug discovery and development
Operator
Good day and thank you for standing by. Welcome to the Q1 2021 Editas Medicine Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions]
I would now like to hand the conference over to your first speaker today, Ron Moldaver, Investor Relations. Please go ahead.
Ron Moldaver
Investor Relations
Thank you, Julian. Good morning, everyone, and welcome to our first quarter 2021 conference call. Earlier this morning, we issued a press release providing our financial results and corporate updates for the first quarter of 2021. A replay of today s call will be available on the Investors section of our website approximately 2 hours after its completion. After our prepared remarks, we will open the call for Q&A.
Published: May 03, 2021 By Brandon May
Clinical-stage precision medicine company
Relay Therapeutics has brought two new senior level management team members into the fold, including Tara O’Meara, who has been appointed to senior vice president of clinical development operations.
O’Meara previously served at bluebird bio, first as a leader in the development and execution of the clinical program for rare genetic disorders and then, most recently, as the clinical development operations department leader overseeing development programs across severe genetic disease and oncology.
Charles Ferté, M.D., Ph.D., another new hire at Relay, was appointed to vice president of global medical lead for RLY-4008, the company’s highly selective FGFR2 Inhibitor that’s being studied for the treatment of certain cancers. Ferté is the former senior director and global project leader at AstraZeneca’s oncology R&D division, overseeing the development of several immune-oncolo
FINDINGS
A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center has identified a novel combination therapy to potentially help overcome resistance to immunotherapy in people diagnosed with advanced lung cancer. The combination approach uses immune checkpoint inhibitors with ATRA, a safe medication that is widely used to treat leukemia. The team found the combination therapy led to eradication of over 70% of tumors when tested in mice with LKB1-deficient lung cancer. It also generated durable tumor-specific immunity.
BACKGROUND
Immune checkpoint inhibitors have substantially improved the outcomes for people with lung cancer. The five-year survival rate for patients with advanced disease on this therapy is more than 13% compared to 5% in patients with conventional chemotherapy. Although immunotherapy has been successful for many patients, a majority of patients still do not respond to the therapy.
/PRNewswire/ Global Institute of Stem Cell Therapy and Research (GIOSTAR), the pioneer in the field of stem cell science and regenerative medicine, was.